Unplanned pregnancy on a direct oral anticoagulant (Rivaroxaban): A warning

Obstetric Medicine

Volumn 9, Issue 1, 2016, Pages 40-42

  Myers, B ^a,b   Neal, R ^c   Myers, O ^a   Ruparelia, M ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b LINCOLN COUNTY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Anticoagulants; direct oral anticoagulants; heavy menstrual bleeding; pregnancy; Rivaroxaban

Indexed keywords

ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; OXYTOCIN; RIVAROXABAN;

ADULT; ARTICLE; CARDIOTOCOGRAPHY; CASE REPORT; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MENSTRUATION DISORDER; PRIORITY JOURNAL; UNPLANNED PREGNANCY; UTERUS RUPTURE; VAGINA BLEEDING; YOUNG ADULT;

EID: 84960412030     PISSN: 1753495X     EISSN: 17534968     Source Type: Journal    
DOI: 10.1177/1753495X15621814     Document Type: Article

References (12)

1. O.KoenigsbrueggeM.LangerM.Hayde. Oral anticoagulation with rivaroxaban during pregnancy: A case report. Thromb Haemost2014; 112: 1323–1324.
2. Electronic Medicines Compendium (eMC). Summary of product characteristics, https://www.medicines.org.uk/emc/medicine/30506 (accessed 18 November 2015)
3. Electronic Medicines Compendium (eMC). Summary of product characteristics, https://www.medicines.org.uk/emc/medicine/25586/SPC/Xarelto+20mg+film-coated+tablets/ (accessed 18 November 2015)
4. European Medicines Agency. CHMP assessment report for Xarelto, Doc.Ref:EMEA/543519/2008, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000944/WC500057122.pdf (accessed 18 November 2015)
5. Electronic Medicines Compendium (eMC). Summary of product characteristics, https://www.medicines.org.uk/emc/medicine/24839 (accessed 18 November 2015)
6. Electronic Medicines Compendium (eMC). Summary of product characteristics, http://www.medicines.org.uk/emc/medicine/27220 (accessed 18 November 2015)
7. Reducing the risk of venous thromboembolism during pregnancy and the puerperium. RCOG Green-top Guideline No. 37a, April 2015, https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37a.pdf
8. S.M.BatesI.A.GreerS.Middeldorp. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th edition). Chest2012; 141: e691S–736S.
9. M.FerreiraS.BarsamJ.P.Patel. Heavy menstrual bleeding on rivaroxaban. Br J Haem2015; 162: 717–718.
10. N.De CremK.PeerlinckT.Vanassche. Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists. Thromb Haemost2015; 136: 749–753.
11. F.Y.HuqK.TvarkovaA.Arafa. Menstrual problems and contraception in women of reproductive age receiving oral anticoagulation. Contraception2011; 84: 128–132.
12. K.R.CulwellK.M.Curtis. Use of contraceptive methods by women with current venous thrombosis on anticoagulant therapy: A systematic review. Contraception2009; 80: 337–345.